Alerts will be sent to your verified email
Verify Email
BAFNAPH
|
Bafna Pharma
|
Everest Organics
|
Brooks Laboratories
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
-52.11 % | 12.73 % | -23.88 % |
|
5yr average Equity Multiplier
|
3.77 | 3.91 | 1.78 |
|
5yr Average Asset Turnover Ratio
|
0.42 | 1.13 | 0.6 |
|
5yr Avg Net Profit Margin
|
-36.55 % | 2.92 % | -23.79 % |
|
Price to Book
|
4.4 | 5.65 | 3.83 |
|
P/E
|
45.16 | 63.77 | 0.0 |
|
5yr Avg Cash Conversion Cycle
|
0.18 Days | -87.83 Days | -10.34 Days |
|
Inventory Days
|
87.65 Days | 61.25 Days | 93.5 Days |
|
Days Receivable
|
132.64 Days | 142.15 Days | 66.75 Days |
|
Days Payable
|
210.48 Days | 226.8 Days | 179.8 Days |
|
5yr Average Interest Coverage Ratio
|
-5.68 | 3.02 | -11.84 |
|
5yr Avg ROCE
|
-11.61 % | 19.01 % | -15.03 % |
|
5yr Avg Operating Profit Margin
|
-21.98 % | 6.68 % | -13.23 % |
|
5 yr average Debt to Equity
|
1.41 | 0.84 | 0.21 |
|
5yr CAGR Net Profit
|
12.0 % | -58.15 % | 0.22 % |
|
5yr Average Return on Assets
|
-16.11 % | 3.96 % | -14.62 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
75.0 % | 60.99 % | 52.62 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-15.12 % | -13.16 % | -13.79 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 9.9 % |
|
Bafna Pharma
|
Everest Organics
|
Brooks Laboratories
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|